Drug Profile
Estradiol/drospirenone - Bayer HealthCare Pharmaceuticals
Alternative Names: Angeliq; Angeliq Low Dose; Angeliq low-low; BAY-864891; E2+DRSP; E2-DRSP; Estradiol/drospirenoneLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma
- Class Androstenes; Antiandrogens; Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Oral contraceptives; Progesterone congeners; Small molecules
- Mechanism of Action Aldosterone antagonists; Estrogen receptor agonists; Mineralocorticoid receptor antagonists; Progesterone receptor agonists; Testosterone congener inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Menopausal syndrome; Postmenopausal osteoporosis
- Discontinued Hypertension; Pregnancy
Most Recent Events
- 02 Feb 2015 Discontinued - Phase-II for Pregnancy (Prevention) in Germany (PO)
- 02 Feb 2015 Launched for Menopausal syndrome in Switzerland, Mexico, Chile, Brazil, Argentina, Russia, Ukraine, Indonesia, Hong Kong, Thailand, Malaysia, Turkey, Israel, China, Canada, Australia and Philippines (PO)
- 02 Feb 2015 Launched for Postmenopausal osteoporosis (Prevention) in Switzerland, Mexico, Chile, Brazil, Argentina, Russia, Ukraine, Indonesia, Hong Kong, Thailand, Malaysia, Turkey and Israel (PO)